Jody Engel News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jody engel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jody Engel Today - Breaking & Trending Today
Ottawa, Ontario (Newsfile Corp. - November 23, 2021) - Innovative Medicines Canada (IMC) is pleased to announce that Cole C. Pinnow, President, Pfizer Canada ULC, has been elected Chair of its Board ....
Knight Therapeutics Reports Second Quarter 2021 investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Knight Therapeutics Announces Health Canada Approval for NERLYNX® to Treat HER2-Positive Metastatic Breast Cancer investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Author of the article: GlobeNewswire Publishing date: Mar 01, 2021  â¢Â March 1, 2021  â¢Â 3 minute read  â¢Â Article content MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) â Knight Therapeutics Inc. (TSX: GUD), (âKnightâ) a pan-American (ex-USA) specialty pharmaceutical company, announced today the Canadian commercial availability of IBSRELA (tenapanor), a first-in-class therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Knight has the exclusive right to commercialize IBSRELA in Canada under the terms of a license agreement entered into with Ardelyx, Inc. (NASDAQ: ARDX) in March 2018, which license agreement also provides Knight with exclusive rights to commercialize tenapanor for hyperphosphatemia in Canada.  IBSRELA was approved by Health Canada on April 15, 2020 and is now covered by most private insurance companies in Canada. ....
Knight Therapeutics Inc. a pan-American specialty pharmaceutical company, announced today the Canadian commercial availability of IBSRELA a first-in-class therapy for the treatment of irritable bowel syndrome with constipation in adults. Knight has the exclusive right to commercialize IBSRELA in Canada under the terms of a license agreement entered into with Ardelyx, Inc. in March 2018, which license agreement also … Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today the Canadian commercial availability of IBSRELA (tenapanor), a first-in-class therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Knight has the exclusive right to commercialize IBSRELA in Canada under the terms of a license agreement entered into with Ardelyx, Inc. (NASDAQ: ARDX) in March 2018, which license agreement also provides Knight with exclusive rights to commercialize tenapanor for hyperpho ....